8 results about "Murine tumor" patented technology

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The application discloses a kind of mouse tumor cell culture devices, including device ontology, multiple placing racks are installed in device ontology, multiple placing racks top are all set with placing groove, the inside of multiple placing racks is all provided with access mechanism, access mechanism includes multiple placing plate, the inside of multiple placing plate is all separated into multiple placing chamber by multiple partition, the inside of multiple placing chamber is provided with correction mechanism, and drive mechanism is provided in device ontology.In the application, when multiple culture dishes need to be placed in the device ontology for cultivation, the access mechanism provided in the device ontology can be used to place the multiple culture dishes one by one, without manually placing and adjusting the spacing of the multiple culture dishes repeatedly, improving the efficiency of placing the multiple culture dishes in the device ontology, reducing the time of the culture dishes in the external environment, and improving the survival rate of mouse tumor cell cultivation.

The invention discloses a fusion protein of neutrophil elastase as well as a preparation method and application of the fusion protein. The fusion protein comprises an optimized human neutrophil elastase (ELANE) fragment and an optimized human alpha2-macroglobulin (A2M) fragment; the amino acid sequence of the fusion protein is as shown in SEQ ID NO.8. The use of ELANE is limited due to intolerance to serine protease inhibitors (such as alpha-1-antitrypsin, A1AT). The optimized ELANE fragment and the optimized A2M fragment are connected to form the fusion protein, the fusion protein has high enzymatic activity, the tolerance to A1AT is greatly improved, and 83.3% of enzyme activity can still be maintained after the fusion protein acts for 2 hours through high-concentration A1AT (19200 nM). The fusion protein can efficiently eliminate mouse tumors and is safe to mice. The fusion protein is simple in preparation process and easy to industrially amplify, and a new strategy is provided for tumor treatment.

The invention discloses a PD-1 / PD-L1 immunotherapy acquired drug-resistant mouse subcutaneous tumor model construction method based on in-vivo multi-dimensional immune landscape evolution, and relates to the field of animal model construction. Comprising the following steps: preparing tumor cells: resuscitating and amplifying an MC38 colonic adenocarcinoma cell strain, and preparing a single-cell suspension; establishing a basic model: inoculating the MC38 single-cell suspension under the skin of a homologous C57BL / 6 mouse, and establishing a tumor-bearing mouse model; drug resistance induction and screening: after the tumor grows to a predetermined volume, applying continuous treatment pressure of an anti-PD-1 or anti-PD-L1 antibody to the tumor-bearing mouse. Firstly, the tumor volume of mice in a treatment group is compared with the average volume of a control group at the same time point, response mice with the tumor volume obviously smaller than that of the control group are screened out, and primary drug-resistant individuals are excluded. Performing dynamic immune monitoring sampling; and processing and analyzing the sample. The preclinical model has the characteristics of repeatability and dynamic monitoring, and overcomes the defects of the existing preclinical model.

This invention belongs to the field of medicinal chemistry, specifically relating to ionizable phospholipids for nucleic acid delivery and their applications. The technical problem this invention aims to solve is the limited variety of ionizable phospholipids currently available for preparing LNPs for mRNA delivery. The technical solution of this invention is to provide a novel ionizable phospholipid molecule that can be used to prepare nucleic acid delivery carriers and LNP formulations prepared based on it. LNP formulations prepared using the ionizable phospholipids of this invention as raw materials exhibit good stability. Experiments show that the LNPs of this invention can efficiently deliver therapeutic RNA to various human and murine tumor cells and achieve high levels of protein expression, demonstrating unique advantages and promising application prospects in this field.

The disclosure provides methods and compositions, e.g., kits and microarray, for assessing the immune response in a murine tumor model based on the expression of a gene panel that characterizes tumor immune interactions.

This invention relates to the application of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium in the preparation of anticancer drugs, belonging to the field of pharmaceutical technology. The structure of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium is shown in Formula I below. The (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium of this invention can inhibit the growth of gastric cancer cells. By promoting autophagy and mitochondrial fragmentation in gastric cancer cells AGS and HGC-27, it inhibits the proliferation, invasion, and migration of gastric cancer cells and arrests them in the G1 phase. Furthermore, in vivo experiments in mice have confirmed that ZWK-3 can inhibit tumor growth in mice in a significant dose-dependent manner, without affecting mouse body weight or visceral indices. Formula I.

The invention provides a preparation method of black phosphorus-based monatomic nano-enzyme, which comprises the following steps: dispersing a black phosphorus carrier in a solution containing a metal or non-metal precursor in an ultralow temperature environment to form a uniform suspension; irradiating by adopting an ultraviolet light source, and inducing metal or non-metal ions to be directionally anchored at defect sites on the surface of the black phosphorus carrier; a metal / nonmetal-black phosphorus coordination structure is formed through ultralow-temperature light-induced reduction, and the monatomic nano-enzyme is obtained. The invention provides an in-vivo anti-tumor effect of the black phosphorus-based monatomic nano-enzyme material. And the treated mouse tumor can be completely ablated. In the treatment process, the weight of the mouse is not changed, and organs are not damaged, so that the biological safety of the treatment is indicated. Mouse tumor tissues show more serious cell nucleus atrophy and cell apoptosis, which shows that the treatment has excellent clinical application prospects.